Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study
Main finding · Dementia/CDResult — go to the resultOdds ratio 0.90 95% CI 0.79–1.03Authors' conclusion
We observed an association between LDL levels, but not statin treatment, and incident dementia/CD. Although causality cannot be determined by our study, the results are in line with multiple randomised controlled trials. However, to understand the long-term effects of lipid levels and statin treatment on dementia/CD, studies of longer follow-up are still needed.
Study context
- Population
- Patients with T2D from the ADVANCE trial
- Participants
- 11,140 patients
- Exposure
- Baseline LDL cholesterol levels and statin treatment vs no statin treatment
- Outcome
- Composite of:
- Dementia (DSM-IV)
- CD (≥3-point decrement in Mini Mental State Examination score)
- Follow-up
- 5-year follow up
Methodological detailsMultinomial logistic regression
- Multinomial logistic regression
Main finding
Dementia/CD
Odds ratio
0.90
95% CI 0.79–1.03
Statinvs No statin
OR 0.90 (95% CI 0.79–1.03)
As reported in the abstract
- Developed dementia/cognitive decline (CD) (all participants)
- 1827 (16.4%)
- OR of dementia/CD per SD higher baseline LDL cholesterol
- 1.06 (95% CI 1.00-1.14)
Observational data: associations, not effects.
Original publication
Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study. Cardiovasc Diabetol. Published 18 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →